目的：对比分析达沙替尼与伊马替尼治疗慢性髓性白血病的临床疗效。方法收集我院2000年4月～2013年5月期间诊治的慢性髓性白血病患者20例作为研究对象，以随机数字表分组的方式分为试验组（10例）与对照组（10例），对照组患者采用伊马替尼治疗，试验组采用达沙替尼治疗，对两组患者的完全细胞遗传学反应率及不良反应发生率进行分析对比。结果研究结果显示，试验组患者的完全细胞遗传学反应率为80.0%，对照组为50.0%，试验组患者的完全细胞遗传学反应率明显高于对照组（P＜0.05）。同时，试验组不良反应发生率明显低于对照组（P＜0.05）。结论达沙替尼治疗慢性髓性白血病的临床疗效优于伊马替尼。%ObjectiveTo compare the clinical efficacy of dasatinib and imatinib to treat chronic myelogenous leukemia.Methods Collected 20 patients of chronic myeloid leukemia in our hospital from April 2000 to May 2013 as the research object, using random number table to divided into test group (10 cases) and control group (10 cases), the control group was treated by imatinib mesylate, test group was treated with dasatinib, the reaction rates of complete cytogenetic group two patients and adverse reaction rate for comparative analysis.Results The results showed that a complete cytogenetic response rate was 80% in the test group, the control group was 50%, complete cytogenetic response in the test group was significantly higher than that of the control group (P>0.05). At the same time, the occurrence of adverse reaction rate of tes tgroup was lower than that of control group (P<0.05).Conclusion The clinical curative effect of Dasatinib therapy in chronic myeloid leukemia is better than imatinib..
展开▼
